Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$15.56 USD
+0.09 (0.58%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $15.54 -0.02 (-0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRNA 15.56 +0.09(0.58%)
Will VRNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
Other News for VRNA
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
Piper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma price target raised by $5 at Piper Sandler, here's why
Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval
Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy